Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary

BACKGROUND: Cancer of unknown primary (CUP) is a heterogeneous group of metastatic cancers where a primary tissue of origin (TOO) is uncertain. Most patients with CUP have limited treatment options and poor survival outcomes. Immune checkpoint inhibitors (ICIs) can be efficacious in some patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Posner, Atara, Sivakumaran, Tharani, Pattison, Andrew, Etemadmoghadam, Dariush, Thio, Niko, Wood, Colin, Fisher, Krista, Webb, Samantha, DeFazio, Anna, Wilcken, Nicholas, Gao, Bo, Karapetis, Christos S, Singh, Madhu, Collins, Ian M, Richardson, Gary, Steer, Christopher, Warren, Mark, Karanth, Narayan, Fellowes, Andrew, Fox, Stephen B, Hicks, Rodney J, Schofield, Penelope, Bowtell, David, Prall, Owen W J, Tothill, Richard William, Mileshkin, Linda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098268/
https://www.ncbi.nlm.nih.gov/pubmed/36720497
http://dx.doi.org/10.1136/jitc-2022-005809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098268/
https://www.ncbi.nlm.nih.gov/pubmed/36720497
http://dx.doi.org/10.1136/jitc-2022-005809

Ejemplares similares